Investing.com - USANA Health Sciences (NYSE: USNA) reported second quarter EPS of $0.54, $0.11 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $213M versus the consensus estimate of $221.01M.
Guidance
USANA Health Sciences sees FY 2024 EPS of $2.40-$2.55 versus the analyst consensus of $2.77.
USANA Health Sciences sees FY 2024 revenue of $850.00M-$880.00M versus the analyst consensus of $883.50M.
USANA Health Sciences's stock price closed at $45.86. It is up 5.50% in the last 3 months and down -28.11% in the last 12 months.
USANA Health Sciences saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See USANA Health Sciences's stock price’s past reactions to earnings here.
According to InvestingPro, USANA Health Sciences's Financial Health score is "good performance".
Check out USANA Health Sciences's recent earnings performance, and USANA Health Sciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar